MacroGenics Inc. Common Stock (MGNX)

About MGNX

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for t…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

293

Website

www.macrogenics.com/

Fundamentals

1-day range

$3.98$4.15

Market cap

$242.81M

P/E (trailing)

—

P/E (forward)

-3.62

EPS (trailing)

$-1.11

Dividend yield

—

Beta

1.19

Avg. volume

862.4K

Forecasts

4 analyst ratings

MacroGenics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• MGNX

  MacroGenics Inc. Common Stock

  $4.13

  ▲ 1.23%
  Market cap $242.81MP/E —
  $1.29$5.08
• ADAG

  Adagene Inc. American Depositary Shares

  $3.68

  ▼ 5.64%
  Market cap $239.77MP/E —
  $1.3$4.85
• SLGL

  Sol-Gel Technologies Ltd. Ordinary Shares

  $69.41

  ▼ 4.35%
  Market cap $230.38MP/E —
  $21$97.97
• VRXA

  Veraxa Biotech AG Ordinary Shares

  $1.36

  ▼ 5.56%
  Market cap $258.78MP/E —
  $1.32$27.36
• ALXO

  ALX Oncology Holdings Inc. Common Stock

  $2

  ▼ 2.44%
  Market cap $259.71MP/E —
  $0.96$2.66
• ELDN

  Eledon Pharmaceuticals Inc. Common Stock

  $3.19

  ▼ 3.92%
  Market cap $264.75MP/E —
  $1.35$4.6
• IMRX

  Immuneering Corporation Class A Common Stock

  $4.99

  ▼ 4.22%
  Market cap $269.79MP/E —
  $3.86$10.08

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

41.77M

Total value held

$112.11M

Institutional holders

104